Season 2023 Episode 136
Mr. Thian Chew, Executive Chair and CEO of Invion Ltd. (ASX: IVX), sits down with Global One Media to talk about his company’s ongoing development of its unique photodynamic therapy technology for the treatment of cancer and other diseases.
The CEO reveals that the preclinical proof of concept showed the exciting possibility of photodynamic therapy being effective on different types of cancer, given the technology’s capability to destroy the cancer tumor and activate the body’s immune response. He adds that Invion Ltd. plans to start at least two clinical trials this 2023.
Also during the interview, Mr. Chew mentions that Invion Ltd. hopes to make a material difference in the options out there for people suffering from cancer.
Visit our website for more information: https://inviongroup.com/
Published on 2 years, 7 months ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate